We hypothesize that this bicalutamide-pretreated tumor had relative enzalutamide resistance associated with baseline RB1 loss and quickly developed increased RTK signaling and suppressed apoptotic response (MCL1 gains) on enzalutamide. Here, MCL1 is linked to neoplasm.